The following post is a bit long, but, it elucidat
Post# of 157814
(Total Views: 375)
Posted On: 10/09/2025 6:18:53 PM
The following post is a bit long, but, it elucidates a solid mechanism of action that Leronlimab would have against Parkinson's Disease, and Lewey Body Dementia. I would love to get this information to The Michael J Fox Foundation. Michael J Fox is, probably, one of the few people with the means to push forward treatments that could actually successfully treat Parkinson's Disease. The science community is, still, dragging their feet. I bet that it wouldn't cost us a cent, for a feasibility study.
Protein Gone Rogue
The focus is on a protein called α-synuclein. In a healthy brain, it helps nerve cells communicate with one another. In Parkinson’s disease, however, the protein starts to act differently, clumping together into harmful formations.
Most past studies have concentrated on large clusters of the protein, called fibrils, which can be seen in brain tissue from people with Parkinson’s. The new research, though, highlights much smaller and more dangerous shapes: α-synuclein oligomers. These tiny structures appear to puncture nerve cell membranes with microscopic holes.
Scientists Catch Parkinson’s Protein Drilling Holes in Brain Cells https://share.google/vPTFNVxXiFdWYg2YL
Based on recent research, the chemokine receptor CCR5 is a newly identified mediator of alpha-synuclein (α-syn) pathology that contributes to synaptic dysfunction and cognitive impairment in diseases like Parkinson's and Lewy Body dementia. The link is not direct, but rather involves a signaling pathway where CCR5 cooperates with the cellular prion protein (\(PrP^{C}\)). The CCR5-mediated α-synuclein pathology pathway Recent studies, especially one published in Nature in 2024, have detailed the molecular mechanism linking α-syn misfolding to CCR5. The process involves the following key steps: α-synuclein accumulation: Pathological levels of α-synuclein, either from overexpression or exposure to pre-formed fibrils, accumulate in brain regions, such as the hippocampus.\(PrP^{C}\)-CCR5 pathway activation: The accumulated α-syn triggers a molecular pathway that involves the co-action of the cellular prion protein (\(PrP^{C}\)) and CCR5. This mechanism is similar to a pathway previously implicated in Alzheimer's disease pathology.Cofilin dysregulation: The activation of the \(PrP^{C}\)-CCR5 pathway leads to the hyperactivation of a protein called cofilin, which normally regulates the structure of the cellular cytoskeleton. This dysregulation causes the formation of cofilin-actin rods, which are abnormal, rod-shaped structures that disrupt synapses.Dendritic spine impairment: The formation of these cofilin-actin rods leads to damage of the dendritic spines, the small protrusions on dendrites that receive synaptic inputs. This results in synaptic dysfunction, which is directly linked to cognitive deficits.CCR5 upregulation: Studies have also found that CCR5 expression levels are increased in hippocampal neurons overexpressing α-syn and in the brains of patients with Lewy Body dementia, reinforcing CCR5's role in the disease process. Therapeutic implications The discovery of this pathway has identified CCR5 as a promising therapeutic target for treating cognitive decline in synucleinopathies. CCR5 inhibition rescues spine deficits: When researchers treated α-syn-overexpressing neurons with CCR5 antagonists like maraviroc (an FDA-approved drug) or the more potent peptide RAP-103, they found that the formation of toxic cofilin-actin rods was blocked.Cognitive function improves: Blocking CCR5 also restored dendritic spine integrity and rescued cognitive deficits in animal models, showing its potential for treating the memory problems associated with these neurodegenerative diseases.Potential for other dementias: As CCR5 is implicated in similar pathways in Alzheimer's disease and HIV-associated neurocognitive disorders (HAND), CCR5 antagonists may represent a therapeutic approach for multiple forms of dementia.
α-Synuclein triggers cofilin pathology and dendritic spine impairment via a PrPC-CCR5 dependent pathway | Cell Death & Disease https://share.google/Zx4YGpDuwF6ueXdoh
Protein Gone Rogue
The focus is on a protein called α-synuclein. In a healthy brain, it helps nerve cells communicate with one another. In Parkinson’s disease, however, the protein starts to act differently, clumping together into harmful formations.
Most past studies have concentrated on large clusters of the protein, called fibrils, which can be seen in brain tissue from people with Parkinson’s. The new research, though, highlights much smaller and more dangerous shapes: α-synuclein oligomers. These tiny structures appear to puncture nerve cell membranes with microscopic holes.
Scientists Catch Parkinson’s Protein Drilling Holes in Brain Cells https://share.google/vPTFNVxXiFdWYg2YL
Based on recent research, the chemokine receptor CCR5 is a newly identified mediator of alpha-synuclein (α-syn) pathology that contributes to synaptic dysfunction and cognitive impairment in diseases like Parkinson's and Lewy Body dementia. The link is not direct, but rather involves a signaling pathway where CCR5 cooperates with the cellular prion protein (\(PrP^{C}\)). The CCR5-mediated α-synuclein pathology pathway Recent studies, especially one published in Nature in 2024, have detailed the molecular mechanism linking α-syn misfolding to CCR5. The process involves the following key steps: α-synuclein accumulation: Pathological levels of α-synuclein, either from overexpression or exposure to pre-formed fibrils, accumulate in brain regions, such as the hippocampus.\(PrP^{C}\)-CCR5 pathway activation: The accumulated α-syn triggers a molecular pathway that involves the co-action of the cellular prion protein (\(PrP^{C}\)) and CCR5. This mechanism is similar to a pathway previously implicated in Alzheimer's disease pathology.Cofilin dysregulation: The activation of the \(PrP^{C}\)-CCR5 pathway leads to the hyperactivation of a protein called cofilin, which normally regulates the structure of the cellular cytoskeleton. This dysregulation causes the formation of cofilin-actin rods, which are abnormal, rod-shaped structures that disrupt synapses.Dendritic spine impairment: The formation of these cofilin-actin rods leads to damage of the dendritic spines, the small protrusions on dendrites that receive synaptic inputs. This results in synaptic dysfunction, which is directly linked to cognitive deficits.CCR5 upregulation: Studies have also found that CCR5 expression levels are increased in hippocampal neurons overexpressing α-syn and in the brains of patients with Lewy Body dementia, reinforcing CCR5's role in the disease process. Therapeutic implications The discovery of this pathway has identified CCR5 as a promising therapeutic target for treating cognitive decline in synucleinopathies. CCR5 inhibition rescues spine deficits: When researchers treated α-syn-overexpressing neurons with CCR5 antagonists like maraviroc (an FDA-approved drug) or the more potent peptide RAP-103, they found that the formation of toxic cofilin-actin rods was blocked.Cognitive function improves: Blocking CCR5 also restored dendritic spine integrity and rescued cognitive deficits in animal models, showing its potential for treating the memory problems associated with these neurodegenerative diseases.Potential for other dementias: As CCR5 is implicated in similar pathways in Alzheimer's disease and HIV-associated neurocognitive disorders (HAND), CCR5 antagonists may represent a therapeutic approach for multiple forms of dementia.
α-Synuclein triggers cofilin pathology and dendritic spine impairment via a PrPC-CCR5 dependent pathway | Cell Death & Disease https://share.google/Zx4YGpDuwF6ueXdoh
(14)
(0)